Medacta Group SA · SIX:MOVE

Medacta Group SA — FY2020 Earnings Presentation

11 slides from Medacta Group SA's earnings presentation, Jan 21, 2021

  1. Slide 1: FY 2020 Preliminary Unaudited Top-Line Figures

    FY 2020 Preliminary Unaudited Top-Line Figures 21 January 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou

  3. Slide 3: Medacta continues to outperform the market with strong 2H 2020 revenue acceleration

    Medacta continues to outperform the market1 with a strong revenue acceleration in the second semester 20202  FY 2020 revenues were €302.5 million, only -2.1% on a constant currency basis, -2.6% reported vs 2019  2H revenues to €167.7 million, +7.6% on a constant currency basis, largely compensatin

  4. Slide 4: 1H – 2H: Revenue Trend

    1H – 2H: Revenue1 Trend (€m) -2.1% -2.6% +7.6% -12.2%  2H revenues largely compensating 1H results  2H acceleration sustained by both pent-up demand and new customers acquired  Starting at the end of October the backlog recovery was limited by Covid-19 second Notes: wave 1. Unaudited figures 4

  5. Slide 5: 1H – 2H: Revenue Growth Comparison by Product Line

    1H – 2H: Revenue1 Growth Comparison by Product Line 1H Growth (%)2 2H Growth (%)2 -17.5% Hip Hip 5.6% -13.0% Knee Knee 4.1% Extremities3 41.7% Extremities 3 50.3% Spine 11.9% Spine 16.6% -12.2% 1H20 CC Growth 7.6% 2H20 CC Growth  Since June the growth was driven by backlog recovery and acquisition

  6. Slide 6: 1H – 2H: Revenue Growth Comparison by Geographic Area

    1H – 2H: Revenue1 Growth Comparison by Geographic Area 1H Growth (%)2 2H Growth (%)2 -17.3% Europe Europe 6.3% -14.3% NA NA 11.0% APAC 5.8% APAC 12.0% -28.4 RoW -29.9% RoW 7.6% 2H20 CC Growth -12.2% 1H20 CC Growth  In Europe and NA the backlog recovery was limited by Covid-19 second wave starting i

  7. Slide 7: FY Revenue Bridge by Product Line

    FY Revenue1 Bridge by Product Line (€m) -6.1% -4.1% 46.6% 14.6% (€m) 14.3; 28.9; 5% 9% 153.1; 106.2; 51% 35% 2 Hip Knee Extremities Spine  Core business (Hip and Knee) was affected by postponement of elective procedures in 1H, partially compensated by an effective backlog recovery  The Extremities

  8. Slide 8: FY Revenue Bridge by Geographic Area

    FY Revenue1 Bridge by Geographic Area (€m) -6.0% -1.0% 9.2% -29.2% (€m) 8.5; 3% 72.0; 24% 129.3; 43% 92.7; 30% Europe NA APAC ROW  In Europe the most affected markets were France, Italy and Belgium; the “DACH” area recorded the smallest impact with Germany growing over the prior year  In NA our in

  9. Slide 9: Conclusions

    Conclusions  Covid-19 pandemic continues to determine uncertainty across all geographies  The orthopaedic market confirmed its resilience with a pent-up demand following lockdown periods  Medacta’s well balanced global geographic presence and product mix positioning allow to benefit in terms of d

  10. Slide 10: Q&A

    Adedacta Q&A

  11. Slide 11: Medacta International

    Adedacta Adedacta International

Medacta Group — FY2020 Earnings Presentation on 6ix